Mast cell density and the context of clinicopathological parameters and expression of p185,estrogen receptor,and proliferating cell nuclear antigen in gastric carcinoma

AIM:To investigate the relationship between the mast cell density(MCD)and the context of clinicopathological parameters and expression of p185,estrogen receptor(ER), and proliferating cell nuclear antigen(PCNA)in gastric carcinoma. METHODS:Mast cell,p185,ER,and PCNA were detected using immunohistochemical S-P labeling method.Mast cell was counted in tissue of gastric carcinoma and regional lymph nodes respectively,and involved lymph nodes(ILN)were examined as usual. RESULTS:MCD was significantly related to both age and depth of penetration(x^2=4.688,P<0.05 for age and x^2=9.350, P<0.01 for depth of penetration)between MCD>21/0.03 mm^2 and MCD≤21/0.03 mm^2 in 100 patients;MCD in 1-6 ILN group patients was significantly higher than that in 7-15 ILN or>15 ILN group patients(u=6.881,8.055,P<0.01); There were significant differences intergroup in positive expression rate of p185,ER and PCNA between MCD>21/ 0.03 mm^2 and MCD≤21/0.03 mm^2 in 100 patients. CONCLUSION:Mast cell may have effect on inhibiting invasive growth of tumor,especially in the aged patients; The number of mast cells,in certain degree,may predicate the number of involved lymph nodes,which is valuable for assessment of prognosis;MCD was related to the expression of p185,ER,and PCNA in gastric carcinoma.It suggests that mast cell accumulation may inhibit the proliferation and the dissemination of the gastric carcinoma. INTRODUCTION Recently,many studies have reported on the association of mast cell with various tumorst.In several malignancies,mast cell has been found to correlate with growth,penetration and prognosis of tumor.Therefore,our study was undertaken to investigate the relationship between the mast cell density (MCD)and the context of clinicopathological parameters and expression of p 185,estrogen receptor(ER),and proliferating cell nuclear antigen(PCNA)in gastric carcinoma.

EGFR、p53、Bcl-2表达,Ki-67标记指数与胸腺瘤WHO组织学分型、分期及预后的关系

目的探讨EGFR、p53、Bcl-2表达,Ki-67标记指数(Ki-67Li)与胸腺瘤WHO组织学分型、分期及预后的关系。方法应用免疫组化染色方法检测46例胸腺瘤患者EGFR、p53、Bcl-2的表达和Ki-67标记指数。结果胸腺瘤EGFR、p53、Bcl-2阳性表达率分别为34.8%、56.5%、54.3%,Ki-67标记指数平均值为11.0%。EGFR、p53、Bcl-2蛋白表达与胸腺瘤WHO组织学分型均无明显关系;B2、B3、C型与A、AB、B1型之间Ki-67标记指数表达差异有显著性(P<0.05);Bcl-2蛋白表达与胸腺瘤Masaoka分期和预后均无关系(P>0.05);EGFR、p53蛋白的过度表达和Ki-67标记指数与胸腺瘤Masaoka分期明显相关(P<0.05);Ki-67标记指数与预后有关(P<0.05)。结论EGFR、p53蛋白的过度表达和Ki-67标记指数与胸腺瘤Masaoka分期明显相关,反应其侵袭性,Ki-67标记指数还与组织学分型相关,并可作为估计胸腺瘤预后的参考指标。

Neoadjuvant targeted therapy for apocrine carcinoma of the breast:A case report

BACKGROUND Apocrine carcinoma of the breast is a special type of invasive ductal carcinoma of the breast that is rare in clinical practice.Neoadjuvant therapy,especially neoadjuvant targeted therapy,has rarely been reported for apocrine carcinoma of the breast.CASE SUMMARY A 63-year-old woman presented with apocrine carcinoma of the left breast underwent core needle biopsy.The patient was diagnosed with apocrine carcinoma by immunohistochemical staining and negative hormone status(estrogen receptor and progesterone receptor)but showed overexpression of human epidermal factor receptor 2(HER-2).Moreover,positive expression of androgen receptor(approximately 60%)and gross cystic disease fluid protein 15 was observed.The patient was treated with neoadjuvant targeted therapy consisting of the TCH regimen(docetaxel,carboplatin area under curve 6 and trastuzumab)every 21 d.The mass in the left breast was significantly reduced,and pain in the breast and left upper arm also improved.CONCLUSION HER-2 positive apocrine carcinoma of the breast can be improved by neoadjuvant chemotherapy combined with targeted therapy.

甲状腺乳头状癌中C-erbB-2、Ki-67的表达及意义

目的 探讨C-erbB-2基因蛋白、Ki-67基因蛋白在甲状腺乳头状癌的表达及临床意义.方法 应用免疫组织化学SP法检测C-erbB-2、Ki-67在45例甲状腺乳头状癌、50例结节性甲状腺肿伴乳头状增生组织的表达.结果 在甲状腺乳头状癌中C-erbB-2阳性表达率为46.67%（21/45）、Ki-67阳性表达率为42.22%（19/45）;C-erbB-2、Ki-67在甲状腺乳头状增生中均呈低表达,阳性率分别为18.00%（9/50）、12.00%（6/50）,两组间阳性表达率差异均有统计学意义（P＜0.01）.在甲状腺乳头状癌中,C-erbB-2阳性表达与淋巴结转移、分化程度及临床分期有关（P＜0.05）;Ki-67阳性表达与淋巴结转移及临床分期有关（P＜0.05）,分化较差者Ki-67阳性表达高于分化较好者,但差异无统计学意义（P＞0.05）.结论 C-erbB-2、Ki-67在甲状腺乳头状癌中起重要的调控作用,是判断其预后的重要参考指标.

EGFR、Her-2、HIF-1α在食管鳞癌的表达及意义

目的研究EGFR、Her-2和HIF-1α在食管鳞癌中的表达,探讨三者的表达与食管鳞癌临床病理学特征之间的关系及三者之间的相关性。方法应用免疫组化Envision二步法检测80例食管鳞癌的切除标本和40例正常鳞状上皮组织中EGFR、Her-2和HIF-1α的表达。结果 HIF-1α、EGFR、Her-2在食管鳞癌及癌旁正常鳞状上皮组织表达阳性率分别为62.5%vs.0.0%(P=0.000)、67.5%vs.12.5%(P=0.000)和7.5%vs.0.0%(P=0.183)。HIF-1α、Her-2、EGFR表达均与肿瘤细胞分化、TNM分期、淋巴结转移有关,与性别、年龄无关。食管鳞癌中HIF-1α的表达与EGFR、Her-2的表达正相关(r=0.565,P=0.000;r=0.221,P=0.039);食管鳞癌中Her-2与EGFR表达无相关性(r=0.198,P=0.079)。结论 HIF-1α、EGFR在食管鳞癌高表达,可能在食管鳞癌的发生发展中起重要作用,可作为监测肿瘤发生、预测转移和预后的有用指标,有可能成为靶向治疗的新靶点。而Her-2因在食管鳞癌表达阳性率低不适合成为靶向治疗的靶点。

血管内皮生长因子受体-1和血管内皮生长因子受体-2在子癎前期中的表达及临床意义

目的观察胎盘组织中血管内皮生长因子受体-1（VEGFR-1）、VEGFR-2、血浆中可溶性血管内皮生长因子受体-1（sVEGFR-1）及sVEGFR-2的表达水平，并探讨其在子癎前期的临床检测意义。方法ELISA检测正常妊娠期妇女和子癎前期患者血浆中的sVEGFR-1和sVEGFR-2的表达；RT-PCR检测正常妊娠期妇女和子癎前期患者胎盘中VEGFR-1、VEGFR-2、sVEGFR-1和sVEGFR-2mRNA的表达。结果ELISA检测结果显示，正常妊娠组分娩后较分娩前血浆中sVEGFR-1[（4．55±0．31）ng／mlvs（12．33±1．52）ng／m1]水平降低，子癎前期组分娩后血浆中sVEGFR．1[（8．13±0．74）ng／mlvs（77．25±9．47）ng／m1]水平亦降低，两组分娩前后数据变化比较差异有统计学意义（P〈0．01）；正常妊娠组分娩前后血浆中sVEGFR-2分别为（8．74±1．24）ng／ml与（6．43±0．55）ng／ml，而子痫前期组分别为（5．69±0．75）ng／ml与（4．96±0．67）ng／ml；RT-PCR检测结果与其-致。结论子癎前期患者分娩后VEGFR-1血浆水平迅速下降，而VEGFR-2持续低水平表达，提示VEGFR-1可能与子癎前期发病率有关，而子癎前期患者血浆中VEGFR-2水平的降低可作为内皮功能障碍的标志。

血管内皮生长因子及其受体各亚型在心肌梗死大鼠体内的差异性表达

目的研究血管内皮生长因子及其受体（VEGFR）各亚型在心肌梗死（MI）后的心肌修复和重构过程中的表达。方法构建大鼠心肌梗死模型，采用实时荧光定量PCR（RT—PCR）和West-emBlot法测定建模前后VEGF各亚型的表达。结果VEGF的所有亚型在正常大鼠心肌细胞中都会表达；与假手术对照大鼠相比，在心肌梗死大鼠心肌内，VEGF-A在MIId时表达为对照组的0．89±0．04倍，42d后显著降低，最低为0．25±0．03倍；VEGF—B在MI中受到显著抑制，最低为对照组的0．09±0．04倍；而VEGF-C和VEGF—D的表达则出现了显著的增加，分别为对照组的5．31±0．21倍和9．24±0．47倍。在MI大鼠心脏内，VEGFR-1和VEGFR~的表达显著减少，分别为对照组的0．11±0．02倍和0．14±0．04倍。而VEGFR-3，主要在血管中的水平则显著增加，是对照组的6．81±0．42倍。结论VEGF和VEGFR的各亚型在心肌梗死大鼠心脏内的表达发生显著性变化，VEGF—A可能是启动血管再生反应的关键调节因子，VEGF—D也是参与血管再生的重要因子，而VEGF—B并不是心肌修复和重构的关键因子。